Internal Medicine, Endocrinology, Diabetes, & Metabolism · Brooklyn, NY
NPI
1770615064
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3131 Kings Hwy Ste B10
Brooklyn, NY, 11234
Phone (347) 462-9292
Groups this clinician bills Medicare through
Medicare paid, 2024
$236K
4,180 services
Medicare patients, 2024
529
Average age 78
Drug cost, 2024
$3.1M
11,530 prescriptions
Company payments, 2025
$49K
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matvey Brokhin was code 99214 (office e&m - established), 1,174 times for 383 patients. In total Matvey Brokhin billed 4,180 services in 16 codes, and Medicare paid $236K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-08-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,174 | 383 | $100.25 | $118K |
| 36415 Venipuncture Blood Collection | Office | 879 | 329 | $8.65 | $7,603 |
| 99212 Office E&M - Established | Office | 864 | 322 | $43.43 | $38K |
| 99232 Hospital E&M - Subsequent | Facility | 745 | 131 | $61.71 | $46K |
| 95251 Test - Miscellaneous | Office | 160 | 60 | $26.49 | $4,239 |
| 99222 Hospital E&M - Initial | Facility | 146 | 131 | $103.03 | $15K |
| 82962 Clinical Chemistry | Office | 143 | 80 | $3.21 | $459 |
| 99204 Office E&M - New | Office | 37 | 37 | $135.85 | $5,026 |
By year: 2022 $301K for 4,991 services; 2023 $310K for 4,988 services; 2024 $236K for 4,180 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 879 | 329 | $8.65 | $7,603 |
| 82962 Clinical Chemistry | 143 | 80 | $3.21 | $459 |
Medicare prescription drug claims, 2024
In 2024, the drug Matvey Brokhin prescribed most often to Medicare patients was Rosuvastatin Calcium, with 1,370 prescriptions and refills. In total Matvey Brokhin wrote 11,530 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 1,370 | 1,786 | 211 | $8,181 |
| Synthroid Levothyroxine Sodium | 1,241 | 1,673 | 158 | $73K |
| Metformin Hcl Generic | 654 | 841 | 88 | $1,364 |
| Repatha Sureclick Evolocumab | 517 | 911 | 95 | $528K |
| Ezetimibe Generic | 437 | 577 | 69 | $3,872 |
| Vascepa Icosapent Ethyl | 393 | 449 | 56 | $93K |
| Alcohol Prep Pads Alcohol Antiseptic Pads | 368 | 479 | 79 | $7,375 |
| Farxiga Dapagliflozin Propanediol | 343 | 421 | 53 | $230K |
| Levothyroxine Sodium Generic | 294 | 445 | 59 | $1,948 |
| Jardiance Empagliflozin | 280 | 353 | 48 | $198K |
| Repaglinide Generic | 267 | 328 | 34 | $3,763 |
| Tresiba Flextouch U-100 Insulin Degludec | 252 | 431 | 48 | $137K |
| Easy Touch Alcohol Prep Pads Alcohol Antiseptic Pads | 251 | 334 | 53 | $1,061 |
| Ozempic Semaglutide | 237 | 296 | 34 | $269K |
| Nexlizet Bempedoic Acid/Ezetimibe | 215 | 279 | 41 | $109K |
Brand drugs: 5,408 claims; generic drugs: 4,365 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matvey Brokhin $49K ($49K in general payments such as food, travel and fees) from 22 companies. The largest payer was Amgen Inc. with $30K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 59 | $30K |
| Xeris Pharmaceuticals, Inc. | 33 | $14K |
| Astellas Pharma US Inc 4503.T | 17 | $599 |
| Ascendis Pharma Endocrinology Inc ASND | 20 | $588 |
| Amneal Pharmaceuticals LLC AMRX | 19 | $543 |
| Chiesi USA, Inc. | 13 | $478 |
| Abbvie Inc. ABBV | 22 | $474 |
| Novo Nordisk Inc NVO | 24 | $471 |
| Esperion Therapeutics, Inc. ESPR | 20 | $453 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 22 | $453 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.